CurrentUnitedHealthcarePolicy 2025 P 1142-12

Ruconest (C1 esterase inhibitor [recombinant]) prior authorization

UnitedHealthcare prior authorization program for Ruconest for treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents; governs coverage and authorization requirements for members under UnitedHealthcare plans (state mandates and member-specific benefits may apply).

Policy Summary

PayerUnitedHealthcare

PolicyRuconest (C1 esterase inhibitor [recombinant]) prior authorization

Policy CodePolicy 2025 P 1142-12

Change TypeNo material change

Effective DateOct 1, 2025

Next Review Date

Key ActionSubmit prior authorization; approvals are issued for 12 months when criteria are met (diagnosis of HAE, use for acute attacks, and not combined with other acute HAE products).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

10+P&T approval years

adults & adolescentsindicated population

laryngeal attacksnot established for

Coverage Criteria for Ruconest (recombinant C1 esterase inhibitor)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Authorization

Covered when ALL of the following are met:

Initial Authorization Criteria: 1. Diagnosis of hereditary angioedema (HAE)

Initial Authorization Criteria: 2. Used for the treatment of acute HAE attacks

Initial Authorization Criteria: 3. Not used in combination with other products indicated for acute HAE attacks (e.g., Berinert, Firazyr, Kalbitor)

The available evidence does not establish effectiveness of Ruconest for laryngeal attacks in hereditary angioedema (HAE) patients. Clinical trial and regulatory language explicitly states that effectiveness was not established for laryngeal manifestations, and the policy excludes laryngeal attacks from proven indications.

Provider Actions and Prior Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required. Approval issued for 12 months when criteria are met.

Authorization duration: 12 months
Affected product: Ruconest (for acute HAE attacks)

Step Therapy

Step Therapy / Automated Approval

Step therapy is not explicitly required. UnitedHealthcare may use automated approval and re-approval processes based on prior claim/medication history, diagnosis codes (ICD-10), and/or claim logic; use of these automated pathways varies by program or therapeutic class.

Automated approval/re-approval may be utilized based on prior claims and ICD-10 diagnosis codes
Supply limitations may be applied

Documentation Required

Approval Pathways and Documentation Sources

Decisions may rely on prior claims, medication history, ICD-10 diagnosis codes, and claims logic as documentation sources for approval and re-authorization.

Possible documentation sources: prior claims, medication history, ICD-10 diagnosis codes, claim history/logic
State mandates and member-specific benefit plans may affect coverage

Denial Risk

Concurrent Therapy Exclusion

Concurrent use of Ruconest with other acute HAE products will not meet criteria and is excluded.

Do not use Ruconest in combination with other acute HAE products (e.g., Berinert, Firazyr, Kalbitor)

Definitions

HAE — definition / brief condition description

ConditionHereditary angioedema (HAE)

Typical presentationRecurrent acute angioedema attacks treated with Ruconest in adults and adolescents

Indicated use for RuconestTreatment of acute attacks in adult and adolescent patients with HAE

Limitations of effectivenessEffectiveness was not established in HAE patients with laryngeal attacks

Drug classC1 esterase inhibitor (recombinant)